RNA sequencing‑based identification of potential targets in acute myeloid leukemia: A case report
- Omar S. El‑Masry
- Ali M. Al‑Amri
- Ahlam Alqatari
- Khaldoon Alsamman
Affiliations: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province 34212, Kingdom of Saudi Arabia, Department of Internal Medicine/Oncology, College of Medicine, Imam Abdulrahman Bin Faisal University, King Fahd Hospital of The University, Al‑Khobar, Eastern Province 34445, Kingdom of Saudi Arabia, Hematology Laboratory/Hematopathology, College of Medicine, Imam Abdulrahman Bin Faisal University, King Fahd Hospital of The University, Al‑Khobar, Eastern Province 34445, Kingdom of Saudi Arabia
- Published online on: August 27, 2020 https://doi.org/10.3892/br.2020.1349
Copyright: © El‑Masry
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Acute myeloid leukemia (AML) refers to heterogenous types of blood cancer which possess a complicated genomic landscape, and multiple novel mutational alterations are frequently being reported. Herein, a case report of a 37‑year old AML patient is presented, who was diagnosed following laboratory investigation after admission. The patient had thrombocytopenia, and three consecutive blast counts of 40, 30 and 41%, respectively. A blood sample was collected for whole‑genome RNA sequencing to understand the transcriptomic profile at the time of diagnosis and compared with a matched female control. Gene expression was quantified using the RSEM software package. Bioinformatics analysis revealed a significant number of differentially expressed genes in the patient, suggesting a marked change in the transcriptomic landscape in this patient. By mining the bioinformatics data and screening the highly expressed genes with ≥80% probability of gene expression, four novel genes were highlighted that may serve as potential future targets in AML patients; Rh associated glycoprotein, succinate receptor 1, transmembrane‑4 L‑six family member‑1 and ADGRA3, although further validation of their value is required.